Trial Profile
Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; T cell replacement therapy (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 02 Mar 2022 Status changed from recruiting to completed.
- 21 Aug 2019 Status changed from not yet recruiting to recruiting.
- 29 Jul 2019 Planned initiation date changed from 28 Feb 2019 to 1 Sep 2019.